Medical Expert, FAES Farma, Spain
Carlos Sánchez Sierra is a dedicated and innovative Clinical Pharmacologist based in Madrid, Spain, with a passion for advancing drug development and clinical research. With substantial experience in managing and evaluating clinical trials across various therapeutic areas, he has contributed to scientific publications and worked closely with healthcare professionals to develop innovative strategies in pharmacovigilance and medical activities. His proactive nature and commitment to improving patient care through scientific research and collaboration make him a valuable figure in the medical and pharmaceutical industries.
Profile
Orcid
Carlos Sánchez Sierra presents a strong candidate profile for the “Business and Science Partnership Award” due to his extensive experience and demonstrated expertise in clinical pharmacology and drug development.
Strengths for the Award:
Carlos’s career showcases a solid foundation in both the scientific and business aspects of clinical trials and drug development. His role at FAES Farma involves the management and development of clinical trials across multiple phases, which requires not only a deep understanding of pharmacology but also effective project management and strategic planning skills. His responsibilities include preparing and reviewing key trial documents, setting timelines, and liaising with regulatory agencies and CROs, all of which highlight his ability to bridge scientific research with business operations. Furthermore, his experience in presenting clinical trial results and publishing study findings underlines his proficiency in communicating complex scientific data, an essential skill for fostering business and science partnerships.
Carlos’s background is also enriched by his contributions to various committees, such as the Research Ethics Committee and the Pharmacy and Therapeutics Committee. His role in these committees, coupled with his experience in pharmacovigilance and clinical practice, demonstrates a comprehensive understanding of the regulatory and ethical dimensions of drug development. Additionally, his involvement in scientific advisory boards and his proactive approach in collaborating with healthcare professionals and pharmaceutical companies exemplify his commitment to advancing scientific knowledge and integrating it into practical, business-oriented applications.
Areas for Improvement:
One area for potential improvement is the expansion of Carlos’s experience in cross-disciplinary collaborations beyond the clinical and regulatory realms. While his expertise in clinical pharmacology and drug development is well-established, further exposure to business development strategies, market analysis, or strategic partnerships could enhance his ability to drive successful collaborations between business and science. Additionally, focusing on leadership roles or projects that involve large-scale business negotiations could further bolster his profile for awards emphasizing business acumen in scientific contexts.
Education 🎓
Carlos completed his degree in Medicine at Universidad San Pablo CEU, Madrid, in 2017. He also trained as a medical practitioner at Uniwersytecki Szpital Kliniczny w Białymstoku, Poland, during the 2015-2016 academic year. His academic background laid the foundation for his specialization in clinical pharmacology and his subsequent involvement in clinical research and drug development.
Experience 💼
Carlos has amassed rich professional experience, starting as a Clinical Pharmacology Medical Resident at Hospital Clínic de Barcelona (2019-2023), where he worked on multiple clinical trial committees and contributed to pharmacovigilance plans. Currently, he serves as the Medical Expert at FAES Farma, Madrid, where he manages Phase I-III clinical trials, providing scientific support and strategic guidance in collaboration with regulatory agencies and medical departments. His role involves publishing study results and presenting them to key opinion leaders (KOLs), further strengthening his expertise in bridging science and business.
Research Interest 🔬
Carlos’s research interests revolve around drug development, pharmacovigilance, and clinical trials. He is particularly focused on advancing innovative therapies, including CAR-T cell treatments, and optimizing safety and efficacy in pharmacotherapy. His work also includes the evaluation of newly approved drugs, contributing to scientific understanding in fields such as oncology, hematology, and neurology. His passion for clinical research is evident in his collaborations with pharmaceutical companies and his leadership in clinical studies.
Awards 🏅
While specific awards are not listed, Carlos’s nomination for a prestigious award such as the Business and Science Partnership Award would be a testament to his significant contributions to bridging scientific innovation and business strategy. His proactive approach to collaboration, innovation in clinical pharmacology, and leadership in managing clinical trials position him as a strong contender for such accolades in the future.
Publications Top Notes📚
Carlos has contributed to various impactful publications, which include:
“Cariprazine-induced mania: A case-series report” in Bipolar Disorders (2021) [Cited by: 12 articles]
“Antineoplastic drug approvals by EMA and FDA between 2018-2021: Evaluation of potential differences” Oral presentation at EACPT Meeting 2022 [Cited by: 8 articles]
“Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines: A Mass Vaccination Campaign in a Tertiary Hospital” in VigilVacCOVID Study (2022) [Cited by: 5 articles]
“Bioequivalence and Safety of Bilastine 20 mg Orodispersible Tablets” in Drugs R D (2024)
“Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years” in J Investig Allergol Clin Immunol (2024)
Conclusion:
Carlos Sánchez Sierra’s blend of scientific expertise, clinical trial management, and proactive engagement with various stakeholders positions him as a strong contender for the “Business and Science Partnership Award.” His ability to integrate scientific research with practical business applications is evident from his professional achievements and contributions to the field. While there is room for growth in areas related to broader business strategy and cross-disciplinary partnerships, Carlos’s current qualifications and experiences make him a noteworthy candidate for recognizing excellence in bridging business and scientific endeavors.